首页 | 本学科首页   官方微博 | 高级检索  
检索        

康莱特注射液联合特罗凯治疗非小细胞肺癌41例
引用本文:贾英杰,李小江,张莹,孙一予,陈亮,陈立伟.康莱特注射液联合特罗凯治疗非小细胞肺癌41例[J].光明中医,2010,25(2):235-236.
作者姓名:贾英杰  李小江  张莹  孙一予  陈亮  陈立伟
作者单位:天津中医药大学第一附属医院肿瘤科,天津,300193
摘    要:目的观察康莱特注射液联合特罗凯(Erlotinib,Tarceva)治疗非小细胞肺癌的临床疗效。方法41例非小细胞肺癌患者,均有组织病理学或细胞学诊断及可评价的客观指标。采用康莱特注射液100ml,静脉点滴,d1~d21,同时联合Erlotinib口服150mg/天,d1~d21,21天为1个周期,连续治疗2个周期。结果41例患者中获得CR1例,PR16例,SD17例,总有效率为41.5%,临床受益反应率为82.9%,中位生存期(MST)时间为8.1个月,无进展生存期(PFS)为4.7个月,总生存期为6.4个月;生活质量提高为90.2%;主要毒性反应是皮疹、腹泻、胃肠道反应以及肝肾功能轻度损伤等。结论康莱特注射液联合Erlotinib是治疗非小细胞肺癌患者的有效新型方案,副作用可以耐受。

关 键 词:康莱特注射液  特罗凯  非小细胞肺癌  中医肿瘤学

Combination of Kanglaite Injection and Tarceva in the Treatment of Non-Small Cell Lung Cancer
Jia Yingjie,Li Xiaojiang,Zhang Ying,Sun Yiyu,Chen Liang,Chen Liwei.Combination of Kanglaite Injection and Tarceva in the Treatment of Non-Small Cell Lung Cancer[J].Journal of Traditional Chinese Medicine,2010,25(2):235-236.
Authors:Jia Yingjie  Li Xiaojiang  Zhang Ying  Sun Yiyu  Chen Liang  Chen Liwei
Institution:Jia Yingjie Li Xiaojiang Zhang Ying Sun Yiyu Chen Liang Chen LiweiOncology Department,The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300193,China
Abstract:Objective:To observe the clinical effect of Kanglaite injection combined with Tarceva on Non-Small Cell Lung Cancer(NSCLC). Methods:41 patients were enrolled in this study, with histologically or cytologiaclly confirmed NSCLC, all of whom had measurable objective index. Kanglaite injection 100ml, ivdrip, d1~d 21 , while oral Tarceva 150mg/d, d1~d 21 , 21 days in a cycle of two consecutive treatment cycles. Results:There were 1 CR,16 PR and 17 SD patients during the 41 patients. The total response rate was 41.5%;and CBR was 82.9%;and MST was 8.1 months;and PFS was 4.7 months;and overall survival was 6.4 months;improve the quality of life for 90.2%. The major side effects were rash, diarrhea, gastrointestinal reaction and hepatorenal function mild damage. Conclusion:Tarceva plus Kanglaite injection is an effective therapy for the patients with NSCLC. The efficacy and CBR improved, and the toxicities can be tolerated.
Keywords:Kanglaite Injection  Tarceva(Erlotinib)  Non-Small Cell Lung Cancer
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号